PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
First anti-alpha-synuclein antibody to advance into   confirmatory large study in patients with early P arkinson’s disease ; expected to initiate in 2021 Prothena to earn a $60 million   clinical milestone   upon first patient dosed DUBLIN, Ireland , Oct.
View HTML
Toggle Summary Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
View HTML
Toggle Summary Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
DUBLIN, Ireland , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor
View HTML
Toggle Summary Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers, in patients with early Parkinson’s disease Significantly reduced decline
View HTML
Toggle Summary Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
DUBLIN, Ireland , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that
View HTML
Toggle Summary Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
DUBLIN, Ireland , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated
View HTML
Toggle Summary Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
View HTML
Toggle Summary Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline DUBLIN, Ireland , Aug.
View HTML
Toggle Summary Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for
View HTML
Toggle Summary Prothena to Report Second Quarter 2020 Financial Results on August 6
DUBLIN, Ireland , July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it
View HTML
Toggle Summary Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
DUBLIN, Ireland , May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare
View HTML
Toggle Summary Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 million provides funding to advance a broad pipeline DUBLIN, Ireland , May 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a
View HTML
Toggle Summary Prothena to Report First Quarter 2020 Financial Results on May 6
DUBLIN, Ireland , April 29, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020 , after the close of the
View HTML
Toggle Summary Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
DUBLIN, Ireland , April 24, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020 . The meeting will convene as scheduled at The Merrion Hotel , Upper
View HTML
Toggle Summary Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
DUBLIN, Ireland , April 22, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early
View HTML